Previous 10 | Next 10 |
AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that it has completed a review of its business, including the status of its programs, resources, and capabilities. AVROBIO has made the determi...
2023-06-12 11:00:58 ET Avrobio ( NASDAQ: AVRO ) said it has completed the sale of its gene therapy program for the treatment of cystinosis to Novartis ( NYSE: NVS ) for $87.5M in cash, which should extend the biotech company's cash runway into Q4 2024. The sale was for A...
All-cash transaction, full $87.5 million paid at closing Proceeds expected to extend cash runway into Q4 2024 AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced the closing o...
2023-06-07 10:01:47 ET Gainers: Avrobio ( AVRO ) +10% . Cardiff Oncology ( CRDF ) +8% . IceCure Medical ( ICCM ) +7% . Humacyte ( HUMA ) +6% . TScan Therapeutics ( TCRX ) +4% . Losers: Vaxart ( VXRT ) -27% . Carism...
2023-06-07 08:35:50 ET Farmer Bros ( FARM ) +61% expands coffee business with deal for Farmer Brothers' facility Chijet Motor Company ( CJET ) +33% . VersaBank ( VBNK ) +25% Q2 earnings call release SaverOne 2014 ( SVRE ) +25% Additional 40 Instal...
2023-05-23 06:00:00 ET 3 Tips for Handling High Volatility When Trading Penny Stocks Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inhe...
2023-05-22 07:44:42 ET Avrobio, Inc ( NASDAQ: AVRO ) spiked ~69% in the pre-market trading Monday after the clinical-stage biotech announced an agreement to sell its hematopoietic stem cell (HSC) gene therapy program targeted at cystinosis to Novartis ( NYSE: NVS ). ...
All-cash transaction, with full $87.5 million to be paid at closing Proceeds expected to extend cash runway into Q4 2024 AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced an...
All patients remain off oral cysteamine up to 36 months post gene therapy Sustained engraftment and durable reduction in leukocyte cystine levels across all patients Received positive regulatory feedback from US and UK agencies AVROBIO, Inc. (Nasdaq: AVRO), a...
2023-05-12 15:00:44 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...
News, Short Squeeze, Breakout and More Instantly...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potentia...